Treatment Dilemmas in Disseminated Nontuberculous Mycobacterial Infections With Interferon-gamma Autoantibodies

Elizabeth M. King,1,a Victoria K. Weaver,1, and Mary H. Kestler1,2

1University of British Columbia, Vancouver, British Columbia, Canada, and 2British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada

Disseminated Mycobacterium avium complex (dMAC) is typically seen in individuals with impaired cell-mediated immunity and is best described in those with HIV. Recently, cases have been described in otherwise healthy individuals with neutralizing antibodies to interferon-gamma (nIFNγ-autoAb), especially in patients of Southeast Asian descent. Treatment is often refractory to mycobacterial therapies, and the use of rituximab and other immunomodulatory agents has been explored. We report 3 cases of dMAC with nIFNγ-autoAb and review the available literature on treatment strategies to provide a framework for the management of patients with refractory infections in the context of neutralizing antibodies to interferon-gamma.

Keywords. disseminated; interferon-gamma autoantibody; mycobacterium avium complex; nontuberculous mycobacterium.

CASE DESCRIPTIONS

Patient 1

A 44-year-old Filipina woman presented with 5 months of constitutional symptoms, lymphadenopathy, elevated liver enzymes, and pancytopenia. She was found to have disseminated Mycobacterium avium complex (dMAC) involving the lungs, liver, lymph nodes, and bone marrow (Figure 1). After initial negative immunodeficiency workup, neutralizing antibodies to interferon-gamma (nIFNγ-autoAb) were strongly positive. She was treated with azithromycin, ethambutol, and rifabutin. Despite adherence to therapy, her disease progressed with persistent constitutional symptoms, lymphadenopathy, and sputum culture positive for MAC. After 4 months of therapy, she developed hemoptysis secondary to an erosive paratracheal lymph node. Biopsy of the node cultured positive for MAC, which remained susceptible to macrolides. Rituximab (375 mg/m² monthly for 2 months) was added to her antimicrobial therapy, followed by prompt improvement in her symptoms and clearance of sputum cultures. After 2 years of therapy, neck/chest computed tomography (CT) showed no residual disease, nIFNγ-autoAb were decreased but not normalized, and she discontinued therapy. Six months later, she remains asymptomatic without evidence of relapse.

Patient 2

A 53-year-old previously healthy Cambodian woman presented with 3 months of constitutional symptoms, nausea, and vomiting with omental caking, nodularity, and retroperitoneal lymphadenopathy on abdominal CT (Figure 2). Biopsy of an intraabdominal lymph node was culture positive for MAC, and immune workup revealed nIFNγ-autoAb. Because of her inability to tolerate oral medications, she was initially treated with parenteral azithromycin, rifampin, amikacin, and moxifloxacin. Amikacin was stopped after 4 weeks due to sensorineural hearing loss.

After 3 months in the hospital without improvement despite antimicrobial therapy, rituximab (375 mg/m² weekly for 4 weeks) was initiated, followed by marked clinical improvement. She was discharged 6 weeks later on azithromycin, ethambutol, rifampin, and interval rituximab. She discontinued antmycobacterial therapy at 22 months and remains well 8 months later with persistent but improved omental stranding and mesenteric lymphadenopathy on imaging.

Patient 3

A 53-year-old Filipino man with a history of nontyphoidal Salmonella bacteremia presented with 12 months of cough, lymphadenopathy, back pain, and weight loss. He was found to have dMAC involving the lung (Figure 3), lymph nodes, and spine. Sputum and blood cultures were positive for MAC and immune evaluation strongly positive for nIFNγ-autoAb. He was started on azithromycin, rifabutin, ethambutol, and moxifloxacin with initial clinical improvement and clearance of blood cultures. Moxifloxacin was eventually stopped due to tendonitis.

Six months later, he developed new bulky lymphadenopathy in the left neck and axilla. Lymph node biopsy was culture positive for Mycobacterium abscessus subsp. massiliense and was susceptible to amikacin, clarithromycin, and clofazimine, with intermediate susceptibility to linezolid and cefoxitin. Given concern for persistent immune deficiency, he was started on rituximab (375 mg/m² with doses at months 0, 1, 6, and 12). Amikacin, linezolid, and cefoxitin were added to his MAC regimen. Amikacin was stopped at 4 weeks due to nephrotoxicity.
and clofazimine added. Linezolid was discontinued after 4 months due to thrombocytopenia and cefoxitin stopped after 1 year. After 2 years of therapy, nIFNγ-autoAb dropped to half the previous level, and a CT scan showed resolution of disease, prompting discontinuation of therapy. In the subsequent 6 months, he had 1 episode of localized herpes zoster, but no evidence of mycobacterial disease.

Table 1 summarizes all 3 cases of dMAC with nIFNγ-autoAb.

**DISCUSSION**

Since its recognition in 2004, infectious complications of nIFN-γ autoAb have become an emerging concern worldwide [1, 2]. IFN-γ serves a critical role in linking myeloid and lymphoid immune pathways (Figure 4), promoting macrophage activation and differentiation [3]. Impairment of the IFN-γ pathway predisposes to viral (ie, CMV, VZV), bacterial (ie, *Mycobacterium* spp., *Salmonella* spp.), and fungal (ie, *Talaromyces* spp., *Histoplasma* spp., *Cryptococcus* spp.) infections, among which disseminated nontuberculous mycobacterium (dNTM) is the most commonly described [1, 2, 4, 5]. Despite a growing number of reported cases of dNTM with nIFN-γ autoAb, there is currently little guidance on treatment of these infections, a topic of particular importance given the complex and remitting nature of the disease. In this paper, we add to the accumulating evidence to support immunomodulatory therapies, review current treatment strategies, and propose a clinical approach to guide management.

**Presentation and Diagnosis**

These cases reflect many important features of dNTM in the setting of nIFN-γ autoAb. To date, 115 cases of dMAC with nIFN-γ autoAb have been reported, most of which presented with multifocal and advanced disease, typically involving the lymph nodes, lungs, and bone [1, 2, 6, 7]. Although autoantibodies to
Table 1. Demographic, Clinical, and Treatment Characteristics of 3 Cases of Disseminated Mycobacterium avium Complex With Neutralizing Interferon-Gamma Autoantibodies

|                     | Patient 1                  | Patient 2                  | Patient 3                  |
|---------------------|----------------------------|----------------------------|----------------------------|
| Age/gender          | 44 female                 | 53 female                 | 53 male                    |
| Ethnicity           | Filipina                  | Cambodian                 | Filipino                   |
| Comorbidities       | MCTD, HTN, GERD, Fatty liver | GERD, HTN, Dyslipidemia, CAD | T2DM, Salmonella spp. bacteremia, Atrial fibrillation |
| Duration of symptoms before diagnosis | 5 mo                      | 8 mo                      | 12 mo                      |
| Disease extent      | Lung, bone marrow, lymph node, liver | Lymph node, intra-abdominal | Lung, lymph node, bone, bloodstream |
| Immune workup       | HIV Negative               | HIV Negative               | HIV Negative               |
| CD4, CD8 subsets, absolute in µL (%) | CD4 – 380 (38)  CD8 – 230 (23) | CD4 – 500 (33)  CD8 – 780 (52) | CD4 – 360 (60)  CD8 – 80 (13) |
| TB QFT              | Indeterminate              | Indeterminate              | Indeterminate              |
| Initial nIFN-γ-autoAb level (titer in fluorescent intensity; control titers ranging from 173 to 240) | 19 071 (strongly positive) | 19 934 (strongly positive) | 18 278 (strongly positive) |
| Treatment & course  | Primary regimen: AZM, EMB, RFB | AZM, EMB, RIF | AZM, RFB, EMB, FOX, CFZ |
| Drugs discontinued due to toxicity | MXF                        | AMK                        | AMK, LZD, MXF |
| Course              | Refractory to therapy      | Refractory to therapy      | Initial improvement then lymphadenopathy due to M. abscessus |
| Rituximab added after 4 mo | Rituximab added after 3 mo |
| Duration of antimycobacterial therapy | 24 mo                      | 22 mo                      | 24 mo                      |
| nIFN-γ-autoAb titer after rituximab course (in fluorescent intensity) | 11 350 (from 19 071 22 mo earlier) | Testing not performed | 9131 (from 18 278 20 mo earlier) |
| Current status      | Clinically well 6 mo after completing therapy | Clinically well 8 mo after completing therapy | Clinically well 6 mo after completing therapy |

Abbreviations: AMK, amikacin; AZM, azithromycin; CAD, coronary artery disease; CFZ, clofazimine; EMB, ethambutol; FOX, cefoxitin; GERD, gastroesophageal reflux disease; HTN, hypertension; LZD, linezolid; MCTD, mixed connective tissue diseases; MXF, moxifloxacin; QFT, QuantiFERON-TB; RFB, rifabutin; RIF, rifampin; TB, tuberculosis.

Figure 4. IFN-γ pathway: NTM and other intracellular pathogens are engulfed by macrophages (1) producing IL-12 (2), which goes on to stimulate natural killer or T-cell production of IFN-γ (3). IFN-γ promotes macrophage activation and differentiation, linking myeloid and lymphoid immunity pathways (4). IFN-γ autoantibodies act to bind and inactivate IFN-γ (5). Created with BioRender.com. Abbreviations: IFN, interferon; IL, interleukin; NTM, nontuberculous mycobacterium; TNF, tumor necrosis factor.
IFN-γ are predominantly seen in individuals of Southeast Asian descent, cases have also been reported in other ethnicities including Japanese [1], South African [8], British [8], German [9], and South Asian [10]. The predominant Southeast Asian representation likely relates in part to genetic HLA-polymorphisms common in this ethnicity (HLA-DRB1*16:02/DQB1*05:02) [6]. While our cases are the first Canadian cases described, this number will likely grow in areas with prominent Southeast Asian immigration as physicians become increasingly aware of this entity.

Diagnostic delay is common in dNTM with nIFN-γ autoAb. Our cases had symptoms for ~8 months before diagnosis, and all were initially diagnosed as tuberculosis (TB) or malignancy. Bias toward malignancy in particular can lead to delays if sample tissue is placed in formalin and sent only to pathology. The diagnostic gold standard for mycobacterial disease is culture, although rapid molecular methods such as polymerase chain reaction can distinguish between TB and MAC, most reliably on smear-positive samples [11, 12]. As these tests are limited by sensitivity, multiple clinical samples should be sent for culture to increase diagnostic yield [13].

The diagnosis of dNTM is unusual without an underlying immunodeficiency and warrants further interrogation. Clues suggestive of a cell-mediated immune defect include recurrent herpes zoster infections or disseminated salmonellosis, as was seen in Patient 3. In a recent case series from Taiwan of 45 patients with dNTM with nIFN-γ autoAb, 40% had a history of salmonellosis, 62% had herpes zoster, and 27% had both [14]. History of severe infections that rely on IFN-γ for clearance may be an important clue to its dysfunction. Box 1 outlines the suggested approach for a patient with suspected nIFN-γ autoAb.

In addition to ethnicity and recurrent infections, indeterminate QuantiFERON-TB testing (QFT) may also suggest the presence of nIFN-γ autoAb. QFT assays are contingent on release of IFN-γ from mononuclear cells in response to TB-specific antigens. The presence of nIFN-γ autoAb neutralizes any IFN-γ released, resulting in lack of mitogen response and yielding an indeterminate result. In both of our cases where testing was performed, an indeterminant QFT result served as an early clue to nIFN-γ autoAb presence. The role of indeterminant QFT testing as an early indicator of nIFN-γ autoAb is further supported by previous case reports [10, 15, 16] and a prospective study of HIV-negative patients with dNTM [17]. Here, Wu et al. demonstrated that 30 out of 30 patients with nIFN-γ autoAb had indeterminate QFT results due to extremely low or undetectable IFN-γ levels in the mitogen tubes, irrespective of nIFN-γ autoAb serum levels [17]. Thus, an indeterminate QFT test in an otherwise healthy patient with dNTM should prompt investigation for nIFN-γ autoAb, which may decrease diagnostic delay and prevent further invasive tests.

Natural History and Antimicrobial Therapy

As cases accrue, it is evident that the natural history of dNTM with nIFN-γ autoAb varies from that of other immunodeficiencies. In terms of dMAC with nIFN-γ autoAb, mortality is lower than dMAC in other immunocompromised states such as advanced HIV, even with available antiretroviral therapy (ART) [1]. In the largest studies of dNTM with nIFN-γ autoAb [1, 2, 4, 14, 18], the combined mortality rate was ~7% (18/269), compared with 29%–54% associated with HIV in the post-ART era [19, 20]. In contrast, relapse is more common in nIFN-γ autoAb–associated disease, occurring in up to two-thirds of cases, with drug-free remission rates as low as ~15% [1, 4, 14]. While mortality of dNTM with nIFN-γ autoAb is low, a relapsing course is common and poses challenges for long-term management.

Treatment of MAC depends on disease extent and host immune status but generally includes ≥12 months of combination antimicrobial therapy [13]. Few antibiotics have reliable activity against MAC, and in vitro susceptibility testing only consistently predicts activity for amikacin and clarithromycin. Similar to standard MAC regimens, most antibiotic regimens for nIFN-γ autoAb–associated dMAC included a macrolide, ethambutol, and rifampycin (Table 2) [1, 14, 21]. Other agents added included fluoroquinolones, oxazolidinones, clofazimine, amikacin, and carbapenems (Table 2). While optimal treatment duration remains unknown, treatment for nIFN-γ autoAb–associated cases reported in the literature has ranged from 18–31 months to as long as 7 years [1, 4, 14, 18]. Given extended treatment durations, macrolide resistance acquired as a result of prolonged therapy should always be considered in cases of recurrent disease, as this could have significant implications on long-term outcomes. Finally, the role of antimicrobial prophylaxis following therapy remains unknown and represents an important area for future research.

Rituximab Therapy for Refractory Cases

Rituximab is a monoclonal antibody against CD20 on B cells and has emerged as the most promising immune-modulating therapy for refractory nIFN-γ autoAb–associated infections [2, 18, 21–25]. Since its first use for such in 2012 [22], at least 21 cases of treatment with rituximab have been described to date [2, 21–25]. We summarize all cases with available clinical data (12 cases) to further delineate clinical and treatment characteristics (Table 2).

In all cases, rituximab was used in progressive disease despite long-term antimicrobial therapy. Time to rituximab addition varied from 3 to >12 months (Table 2). In most cases, there was improvement or lack of disease progression after initiation of rituximab, with the exception of 2 cases where disease course was more protracted, accompanied by a less robust reconstitution of IFN-γ [22, 26]. In 1 case, progression despite rituximab prompted the addition of daratumumab, a
monoclonal antibody targeting CD38 on multiple immune cells, with subsequent clinical improvement [26]. In cases that responded to rituximab, clinical response occurred ~2 months after initiation [22, 23], but has been reported to occur as early as 10 days [24] and as late as 6 months into therapy [22]. As a whole, the significant improvement seen in the majority of these cases including ours, suggests that rituximab is a promising adjunct in some of the most challenging and refractory cases.

With increasing evidence of effectiveness, there is an urgent need to determine optimal rituximab dosing. The majority of mIFN-γ autoAb cases used a dose of 375 mg/m² initially at

| First Author, Date (Ref) | Demo-graphics | Microbiology | Disease Extent | Antimicrobial Therapy | Time From Diagnosis to Rituximab | Follow-up After First Rituximab Dose, mo | Rituximab Dosing Regimen (Duration of Therapy) |
|--------------------------|----------------|---------------|----------------|------------------------|-----------------------------------|-------------------------------------------|-------------------------------------------------|
| Browne, 2012 [7]         | 46 F Filipino  | M. abscessus, MAC | LN, blood, urine, pelvic abscess, skin | CLR, EMB, INH, LZD, MXF, TGC | >12 | Improvedb | 5 y | 375 mg/m² wkly × 4 doses, then at wider intervals, total 15 doses (3 y) |
| Browne, 2012 [7]         | 69 F Filipino  | M. abscessus | LN, blood, bone | AMK, AMC, AZM, CIP, ETP, EMB, INH, LZD, MEM, PZA, Rif, TGC | >12 | Improvedb | 6 y | 375 mg/m² wkly × 4 doses, then at wider intervals, total 18 doses (3 y) |
| Browne, 2012 [7]         | 50 F Laotian   | MAC | LN, bone, muscle | CLR, EMB, MXF | >12 | Improvedb | 4 y | 375 mg/m² wkly × 4 doses, then at wider intervals, total 11 doses (1 y) |
| Browne, 2012 [7]         | 60 F Vietnamese | M. intracellulare | Bone, muscle, skin | AMK, AZM, CLR, EMB, INH, LVX, MXF, PZA, Rif | >12 | Initially protracted, then improved | 2 y | 375 mg/m² wkly × 4 doses, then at wider intervals, total 9 doses (2 y) |
| Czaja, 2014 [6]          | 78 M Japanese | M. chelonae-abscessus | LN, bone | AZM, IPM, TOB, MXF | 9 | Improved | 8 | 375 mg/m² wkly × 4 doses (1 mo) |
| Naik, 2016 [18]          | 78 F Filipino  | M. abscessus | Bone, blood | AMK, AZM, CIP, ETP, EMB, INH, LZD, MEM, PZA, Rif, TGC | NA | Improved | 5 y | NA |
| Pruetpongpun, 2016 [16]  | 72 M Thai      | M. abscessus, Talaromyces marneffei | LN, lung | INH, Rif, PZA, EMB, AMK, IPM, CLR, CIP | 3 | Improved | 9 | 375 mg/m² wkly × 8 doses (2 mo) |
| Koizumi, 2017 [17]       | 67 F Japanese | MAC | Bone | Rif, CLR, EMB, STFX, AMK, LZD, AZM | 7.5 | Stopped progression | 3 | 375 mg/m² wkly × 4 doses (1 mo) |
| Ochoa, 2020 [19]         | 31 F Filipino  | MAC | Bone, LN, soft tissue | AZM, EMB, MXF, CFZ, MEM, TZD, BDQ | NA | Progression at 6 mo with improvement after initiation of daratumumab | NA | 1 g monthly × 5 mo |
| Our case                 | 44 F Filipino  | MAC | LN, BM, lung, liver | AZM, EMB, RFB, MXF | 4 | Improved | 27 | 375 mg/m² monthly × 2 doses (2 mo) |
| Our case                 | 53 F Cambodian | MAC | LN, intra-abdominal | AZM, Rif, AMK, MXF | 3 | Improved | 28 | 375 mg/m² wkly × 4 doses every 3 mo, total 18 doses (9 mo) |
| Our case                 | 53 M Filipino  | MAC, M. abscessus | LN, lung, bone | AZM, RFB, EMB, MXF, AMK, CFZ, FOX, LZD | 10 | Improved | 20 | 375 mg/m² monthly at 0, 1, 6, 12 mo (12 mo) |

Abbreviations: AMC, amoxicillin-clavulanic acid; AMK, amikacin; AZM, azithromycin; BDQ, bedaquiline; BM, bone marrow; CFZ, clofazimine; CIP, ciprofloxacin; CLR, clarithromycin; EMB, ethambutol; ETP, ertapenem; FOX, ceftoxitin; IFN, interferon; INH, isoniazid; LN, lymph node; LVX, levofloxacin; LZD, linezolid; MAC, M. avium complex; MEM, meropenem; MXF, moxifloxacin; PZA, pyrazinamide; RFB, rifabutin; Rif, rifampin; STFX, sitafloxacin; TOB, tobramycin; TGC, tigecycline; TZD, tedizolid.

*Treatment included IFN-γ infusion.

*Relapse occurred with retreatment and clinical improvement.

*Treatment included plasmapheresis.
weekly dosing intervals, similar to that used in lymphoma (Table 2) [22]. In 1 case of disease that progressed after rituximab treatment, a monthly regimen was used, resulting in a lower cumulative dose. It remains unclear whether increased dosing frequency may have improved response in this case [26]. In our cases, dosing frequency varied considerably due to individual disease burden and health insurance coverage. We saw equally excellent treatment outcomes with a variety of dosing regimens, suggesting that an immune response may be seen after only a few rituximab doses in some individuals.

Clinical, microbiologic, and radiographic assessment are essential to establishing therapeutic response when managing NTM. In some cases, nIFN-γ autoAb levels have additionally been used to monitor response to rituximab [24]. IFN-γ autoAb levels may drop by 30%–40% as early as 4 weeks after rituximab therapy, and antibody-depleting effects can persist for months [21, 22, 24]. Relapse following discontinuation of rituximab therapy was reported in 3 cases, each associated with increased nIFN-γ autoAb levels, suggesting that antibody levels may augment clinical evaluation as a predictor for recurrent disease [22]. For our cases, nIFN-γ autoAb testing is not available in commercial assays in Canada, and autoAb levels were measured by particle-based multiplex assays [2] at a National Institutes of Health research lab in the United States. Because of this, serial testing is limited by cost and turnaround time. For 2 patients, end-of-therapy nIFN-γ autoAb titers were measured and were decreased but not normalized, suggesting the ongoing need for close monitoring of these patients.

**Other Immunomodulatory Therapy for nIFN-γ AutoAb**

Other immunomodulating therapies have been used for refractory disease with varying success. In a review of various treatments, adjunct therapies such as IFN-γ infusions (n = 5), intravenous immunoglobulin (n = 3), and plasmapheresis (n = 1) showed no consistent improvement in refractory disease [27]. The role of cyclophosphamide, a T- and B-cell-depleting agent, has been used successfully in several cases [28, 29]. In a pilot study comparing cyclophosphamide (n = 11) with rituximab (n = 6) for IFN-γ autoAb–associated disease, there was no significant difference in partial or full remission at 6 months between the groups, and those receiving cyclophosphamide had faster and more durable remission [30]. This pilot suggests that cyclophosphamide may be used as an immunomodulatory alternative particularly when access to rituximab is limited. Finally, immunomodulatory therapies generally reserved for hematologic malignancies have also prompted new interest. In a recent case report, R-CHOP (rituximab - cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy was successfully used to treat dMAC with nIFN-γ autoAb, a regimen that was given for lymphoma but resulted in resolution of dMAC hepatic abscesses [31]. Similarly, daratumumab, a monoclonal antibody used in the treatment of multiple myeloma, successfully treated nIFN-γ autoAb–associated disease that was refractory to rituximab [26]. While many of these therapies and their side effects warrant further investigation, together they underscore the growing recognition of immunotherapy as a cornerstone of treating dMAC with nIFN-γ autoAb.

**CONCLUSIONS**

Herein, we present 3 cases of refractory dMAC with nIFN-γ autoAb to illustrate the complexity of disease and propose a framework to guide management (Box 1). Clinicians should suspect underlying nIFN-γ autoAb in otherwise healthy Southeast Asian patients who develop dNTM infections. Management is challenging, requiring long-term antibiotic regimens, and rituximab holds promise for the treatment of refractory disease.

**BOX 1. SUGGESTED APPROACH TO DIAGNOSIS AND MANAGEMENT OF dMAC ASSOCIATED WITH nIFN-γ AUTOAB**

Clinicians should suspect possible nIFN-γ autoAb in otherwise healthy patients with dMAC and the following:
- Southeast Asian heritage
- Negative HIV1/2 testing
- Prior or recurrent severe infections involving the IFN-γ pathway:
  - Viral (CMV, VZV)
  - Bacterial (Mycobacterium spp., Salmonella spp.)
  - Fungal (Talaromyces spp., Histoplasma spp., Cryptococcus spp.)
- Indeterminate QuantiFERON-TB (QFT) result
- No alternate explanation for dMAC (ie, other inherited or acquired immune deficiencies)

Initial antimicrobial therapy should include:
- Macrolide (clarithromycin or azithromycin)
- Ethambutol
- Rifampicin

Further consideration of additional antimicrobials should be based on resistance patterns, refractory disease, or drug intolerance.

Management of refractory/recurrent disease:
- Immunomodulatory therapies such as rituximab should be considered
- Rituximab is generally dosed at 375 mg/m². The ideal dosing interval/duration requires further study. Most collective experience is with a regimen of weekly dosing for at least 4 weeks.
- Monitoring should by clinical, microbiologic, and radiographic follow-up. nIFN-γ autoAb or pSTAT1-alpha levels could be measured serially to assess disease activity when available.
As nIFN-γ autoAb–related infections continue to emerge worldwide, further investigation of long-term management of this entity will be important.

Acknowledgments

We would like to thank Dr. Steven Holland for facilitating IFN-γ autoantibody testing for all 3 patients.

Financial support. There was no financial support received for this report.

Potential conflicts of interest. The authors have no conflicts of interest to report. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Patient consent. Written consent was provided by all patients for inclusion in this report. To protect confidentiality, clinical reporting and images are anonymized. This work conforms to standards applied in Canada, and procedures were in accordance with the standards of the Helsinki Declaration. This work was reviewed and approved by University of British Columbia ethics committee.

Author contributions. Report conception (E.M.K., V.K.W., M.H.K.), chart reviews (E.M.K., V.K.W.), data collection (E.M.K., V.K.W.), literature review (E.M.K., V.K.W.), drafting the manuscript (E.M.K., V.K.W.), and revision of the manuscript (E.M.K., V.K.W., M.H.K.). All authors approved the submitted manuscript version and have agreed to be personally accountable for any questions related to the accuracy or integrity of any part of the work.

References

1. Aoki A, Sakagami T, Yoshizawa K, et al. Clinical significance of interferon-γ neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease. Clin Infect Dis 2018; 66:1239–45.
2. Hong GH, Ortega-Villa AM, Hunsberger S, et al. Natural history and evolution of anti-interferon-γ autoantibody-associated immunodeficiency syndrome in Thailand and the US. Clin Infect Dis 2020; 71:53–62.
3. Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis 2015; 15:968–80.
4. Angkasekwinai N, Suputtamongkod Y, Phoompoung P, et al. Clinical outcome and laboratory markers for predicting disease activity in patients with disseminated opportunistic infections associated with anti-interferon-γ autoantibodies. PLoS One 2019; 14:e0215581.
5. Guo J, Ning XQ, Ding YJ, et al. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections. J Exp Med 2020; 217:e20190502.
6. Chi CY, Chu CC, Liu JP, et al. Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection. Blood 2013; 121:1357–66.
7. Patel SY, Ding L, Brown MR, et al. Anti-IFN-γ gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005; 175:4769–76.
8. Kampmann B, Hemingway C, Stephens A, et al. Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ. J Clin Invest 2005; 115:2480–8.
9. Hanitsch LG, Löbel M, Müller-Redetzky H, et al. Late-onset disseminated Mycobacterium avium intracellulare complex infection (MAC), cerebral toxoplasmosis and Salmonella sepsis in a German Caucasian patient with unusual anti-interferon-gamma IgG1 autoantibodies. J Clin Immunol 2015; 35:361–5.
10. Yerramilli A, Huang GKL, Griffin DWJ, et al. Disseminated nontuberculous mycobacterial infection associated with acquired immunodeficiency due to anti-interferon-γ autoantibodies. Open Forum Infect Dis 2019; 6:XXX–XX.
11. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11:1–196.

12. Rocchetti TT, Silbert S, Gostnell A, et al. Validation of a multiplex real-time PCR assay for detection of Mycobacterium spp., Mycobacterium tuberculosis complex, and Mycobacterium avium complex directly from clinical samples by use of the BD Max Open System. J Clin Microbiol 2016; 54:1644–7.
13. Griffith DE, Ak samt T, Brown-Elliott BA, et al; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367–416.
14. Chi CY, Lin CH, Ho MW, et al. Clinical manifestations, course, and outcome of patients with neutralizing interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore) 2016; 95:e3927.
15. Suarez I, Lehmann C, Gruehl H, et al. Repurposing QuantiFERON for detection of neutralizing interferon-γ autoantibodies in patients with nontuberculous mycobacterial infections. Clin Infect Dis 2017; 65:518–21.
16. Ikeda H, Nakamura K, Ikemori M, et al. Severe disseminated Mycobacterium avium infection in a patient with a positive serum autoantibody to interferon-γ. Intern Med 2016; 55:3053–8.
17. Wu UI, Chuang YC, Sheng WH, et al. Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing interferon-γ autoantibodies in patients with disseminated nontuberculous mycobacterial infection. Clin Microbiol Infect 2018; 24:159–65.
18. Valour P, Perpoint T, Sénéchal A, et al; Lyon TB Study Group. Interferon-γ autoantibodies as predisposing factor for nontuberculous mycobacterial infection. Emerg Infect Dis 2016; 22:114–6.
19. Kobayashi T, Nishijima T, Teruya K, et al. High mortality of disseminated nontuberculous mycobacterial infection in HIV-infected patients in the antiretroviral therapy era. PLoS One 2016; 11:e0151682.
20. Varley CD, Ku IH, Henkle E, Schafer SD, Winthrop KL. Disseminated nontuberculous mycobacteria in HIV-infected patients, Oregon, USA, 2007–2012. Emerg Infect Dis 2017; 23:533–5.
21. Czaja CA, Merkel PA, Chan ED, et al. Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody. Clin Infect Dis 2014; 58:e115–8.
22. Browne SK, Zaman R, Sampao EP, et al. Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection. Blood 2012; 119:3933–9.
23. Pruetpongpun N, Khawcharoenporn T, Damronglerd P, et al. Disseminated Talaromyces marneffei and Mycobacterium abscessus in a patient with anti-interferon-γ autoantibodies. Open Forum Infect Dis 2016; 3:XXX–XX.
24. Koizumi Y, Sakagami T, Nishiyama N, et al. Rituximab restores IFN-γ STAT1 function and ameliorates disseminated Mycobacterium avium infection in a patient with anti-interferon-γ autoantibody. J Clin Immunol 2017; 37:644–9.
25. Naik R, Cortes JA. Persistent Mycobacterium abscessus infection secondary to interferon-γ autoantibodies. Ann Allergy Asthma Immunol 2016; 116:461–2.
26. Ochoa S, Ding L, Kreuzburg S, Treat J, Holland SM, Zerbe CS, Daratumumab (anti-CD38) for treatment of disseminated nontuberculous mycobacteria in a patient with anti-IFN-γ autoantibodies. Clin Infect Dis. In press.
27. Hase I, Morimoto K, Sakagami T, et al. Patient ethnicity and causative species determine the manifestations of anti-interferon-gamma autoantibody-associated nontuberculous mycobacterial disease: a review. Diagn Microbiol Infect Dis 2017; 88:308–15.
28. Baerlecken N, Jacobs R, Stoll M, et al. Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-gamma autoantibody. Clin Infect Dis 2009; 49:e76–8.
29. Chutschitsakd P, Anunattasri S, Nanagara R, et al. Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated Mycobacterium abscessus infection. J Immunol Res 2018; 2018:6743629.
30. Laisuan W, Pisitkun P, Ngamjanyaporn P, et al. Prospective pilot study of cyclophosphamide as an adjunct treatment in patients with adult-onset immunodeficiency associated with anti-interferon-γ autoantibodies. Open Forum Infect Dis 2020; 7:XXX–XX.
31. Uno S, Uehara E, Kimura T, et al. R-CHOP chemotherapy for disseminated Mycobacterium avium complex disease due to anti-interferon-gamma autoantibodies: a case report. Open Forum Infect Dis 2021; XXX–XX.